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Benign prostatic hyperplasia.
Part 2—Management
Timothy J Wilt,1 James N’Dow2
Management of benign prostatic hyperplasia (BPH) is
mainly directed at improving bothersome lower
urinary tract symptoms. The vast majority of men
with these symptoms initially present to primary care
seeking information about the risks and benefits of
available treatments. Few men require urgent referral
to a specialist for additional diagnostic testing or
management. This article provides evidence to guide
primary care doctors in the treatment of men with
lower urinary tract symptoms, with emphasis on BPH.
A previous article discussed diagnosis.1
What treatment options exist?
Treatment goals are to improve bothersome symp-
toms, prevent symptom progression, and reduce
longer term complications (including acute urinary
retention, incontinence, recurrent urinary tract infec-
tions, renal insufficiency, and the need for surgery).2 3
Options include observation (watchful waiting); life-
style management; modification of existing medica-
tions and/or management of coexisting medical
conditions; prostate and bladder specific drug treat-
ment; and major surgical and minimally invasive
surgical treatments (box). Treatment choices are
primarily determined by how severe and bothersome
the symptoms are and by patient preferences for types
of interventions basedon theirweightingof established
effectiveness and adverse effects. Surgery provides the
largest improvement in symptom score (on the
AmericanUrological Association’s international pros-
tate symptom scale), with minimally invasive surgery
producing greater changes in symptom relief than
medical treatments.2 3
Lifestyle management
Many men are reassured to be told that lower urinary
tract symptoms are common in ageing men, typically
progress slowly over time, rarely result in urgent or life
threatening complications, are not due to prostate
cancer, and do not increase their risk of developing
prostate cancer. Simple lifestylemodifications (box) or
adjustment of medications that can worsen urinary
symptoms (such as diuretics) can result in acceptable
improvement.2-4 Participation in self help groups may
also improve outcomes.56
Drug therapy
Monotherapy with α-1 selective adrenergic antagonists or
5α-reductase inhibitors
Formenwithmoderate or severe symptoms that donot
improve satisfactorily with lifestylemanagement, drug
treatments for BPH can be effective (box), with an
average reduction in the international prostate symp-
tom scale (range 0 to 35) of three to six points from
baseline. A four point change in the international
prostate symptom score corresponds with a noticeable
difference by patients and is used to assess the clinical
significance of interventions or symptomprogression.7
On the basis of this criterion, about 60% of men will
notice an improvement of their symptoms with drug
treatment.2-4
Systematic reviews of randomised controlled clinical
trials evaluatingeffectivenessandadverseeffects ofdrug
treatments have shown that in the first year of treatment,
α-1 selective adrenergic antagonists (α blockers) are
more effective than 5α-reductase inhibitors in improv-
ing symptoms.2-4 All α blockers have similar efficacy in
improving symptoms and urinary flow rate, and their
effect is generally maximal within a month of treatment
starting. In most men who respond to an α blocker and
who tolerate it well initially, the drug continues to
work and be well tolerated for many years.4 Head to
head trials of α blockers are few, small, and have
serious methodological limitations.2-48 9 Terazosin and
UNANSWEREDQUESTIONS
 Given the chronic nature of benign prostatic
hyperplasia, are escalating treatment strategies cost
effective compared with one-off treatments (for
example, is a single surgical intervention more cost
effective than many years of drug treatment)?
 Should surgical ablationbeusedasaprimary treatment
or only after failure of drug therapy?
 Do phytotherapeutic compounds improve urinary
symptoms and prevent progression?
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doxazosin require dose titration to minimise adverse
effects at the start (such as dizziness and syncope).
Tamsulosin and alfuzosin do not require dose titration,
but no convincing evidence exists that they cause fewer
cardiovascular adverse effects—such as symptomatic
hypotension—than other α blockers.2-4 89 Few data exist
on the safety of α blockers in men taking drugs for
erectile dysfunction; however, there is no absolute
contraindication to their concomitant use.
Combination therapy
A combination of an α blocker and a 5α-reductase
inhibitor has similar effects on quality of life to an α
blocker alone in the first year and a half of treatment.10
Long term effectiveness of combination therapy on
symptomprogressionandneed for surgerydependson
prostate size as assessed by digital rectal examination,
ultrasonography, or level of prostate specific antigen.
Formenwithmoderate to severe symptoms and a large
prostate (>40 g) on digital rectal examination or
ultrasonography or a baseline level of prostate specific
antigen of >4 ng/ml, combination therapy can prevent
about two episodes of clinical progression per 100men
per year over four years of treatment. Effectivenesswas
considerably less (or non-existent) inmen with smaller
prostates.
Most clinical progression is due to worsening
symptoms rather than development of health threaten-
ing complications or need for surgery (figs 1 and 2).
Disadvantages of the combination therapy described
above compared with an α blocker alone include the
need for treatment for more than a year before a
difference in outcomes is usually noticed; the fact that
most men will have no additional benefit; higher
medication costs; and sexual side effects (from the 5α-
reductase inhibitors), which occur in about four
additional patients per 100.
A possible side benefit of 5α-reductase inhibitors is
their use as primary prevention of prostate cancer—
regardless of the presence or severity of lower urinary
tract symptoms—inmenwith levels of prostate specific
antigen of <4 ng/ml.11 However, the risk of being
diagnosedwith high grade prostate cancer is increased.
Whether this is a true increased presence of high grade
disease or merely a histological or sampling artefact
caused by reduction in prostate size owing to 5α-
reductase inhibitors is not certain.10 If prostate specific
antigen is measured with the aim of detecting prostate
cancer, thresholds for “abnormal” values should be
lowered because 5α-reductase inhibitors reduce the
antigen values by about 50%.11 12
The decision on when to use combination therapy
for lower urinary tract symptoms is complex and
should ideally be based on informed, shared decision
making between patients and providers that incorpo-
rates the above information on benefits and harms for
the urinary symptoms as well as prevention of prostate
cancer.
Phytotherapy
Numerous plant based products (phytotherapy) are
commonlyused for self treatmentof lowerurinary tract
symptoms and can be prescribed in some European
TREATMENTOPTIONS FOR LOWERURINARY TRACT SYMPTOMS
Observation or watchful waiting
No intervention needed beyond explanation and reassurance
Lifestyle modification
Reduce fluidordiuretic intakeand/ormodifybehaviours to reduce theseverityofsymptoms
and reduce thebothersomenatureof thesymptoms:avoidexcessornight-time fluid intake,
caffeine, and alcohol; void the bladder before long trips, meetings, or bed time
Treatment of comorbid contributing conditions
Thismay improvesymptomsand result in reduceddiuresis: improve thecontrol ofdiabetes,
adjust diuretic medications
Drug treatments
Use α antagonists to improve bladder and prostate smooth muscle tone; 5α-reductase
inhibitors to reduce prostate volume; combination therapy with α antagonists plus 5α-
reductase inhibitors; and anticholinergics (for symptoms of an overactive bladder) to
decrease hypercontractility of the detrusor muscle
Major surgical treatments
 Transurethral resection of the prostate: improves urinary symptoms and flow by “coring
out the prostate” through the urethra using instrument with light source
 Transurethral incision of the prostate: for small prostates, relieves urethral narrowing by
using special instrument to make incisions in prostate through urethra
 Otherablativesurgical treatmentsusehigherenergydevices to resector vaporiseprostate
tissue: transurethral laser prostatectomy (resection/enucleation); transurethral laser
prostatectomy (vaporisation); bipolar transurethral resection of the prostate;
transurethral electrovaporisation of the prostate; bipolar transurethral
electrovaporisation of the prostate; transurethral vaporesection of the prostate; bipolar
transurethral vaporesection of the prostate
Minimally invasive surgical treatments
These destroy prostate tissue using low energy devices through coagulative necrosis:
transurethralmicrowave thermotherapy; transurethral needle ablation of theprostate; high
intensity focused ultrasonography; transurethral ethanol ablation of the prostate;
transurethral laser coagulation of the prostate; water thermotherapy
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Fig 1 Cumulative incidence of progression of benign prostatic
hyperplasia in men with moderate to severe symptoms at
baseline.Progressionwasdefinedbyan increaseofat least four
points in the international prostate symptom score, acute
urinary retention, incontinence renal insufficiency, or recurrent
urinary tract infection
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countries. Systematic reviews have suggested that both
saw palmetto and Pygeum africanum provided modest
improvement in urinary symptoms and flow.13 14
However, a recent high quality randomised trial
found that saw palmetto was no more effective than
placebo in men with BPH and moderate to severe
symptoms.15 Ongoing trials are assessing long term
effectiveness and safety of varying doses of both saw
palmetto and Pygeum africanum.
Antimuscarinics for storage problems
For some men, symptoms of storage problems—such
as urinary urgency (with orwithout urge incontinence),
frequency, small urine volumes, and nocturia—in the
absence of serious obstructive symptoms are predomi-
nant. Recently this symptom complex has been
categorised as overactive bladder syndrome. For
these men options such as bladder training, biofeed-
back, and antimuscarinic drugs may be useful either
alone or in combination with treatment that is
more specifically directed at benign prostatic
enlargement.16 17 A systematic review of 56 trials
found that antimuscarinics (oxybutynin, tolterodine,
trospium, solifenacin, and darifenacin) were safe and
efficacious in the treatment of overactive bladder
syndrome. All antimuscarinics except immediate
release oxybutynin were well tolerated.18 Dry mouth
was the most commonly reported adverse event, and
no drug was associated with an increase in any serious
adverse event.
Antimuscarinics should be used with caution inmen
with severe obstructive or voiding symptoms as these
patients may have high residual urine volumes (more
than150ml) andantimuscarinicshavea theoretical risk
of precipitating a deterioration of voiding symptoms
including urinary retention. The evidence for this risk,
however, is weak.
What are the benefits and harms of surgery?
Evidence of effectiveness for minimally invasive
surgical treatments comes from case series and
randomised trials versus transurethral resection of the
prostate, other minimally invasive treatments, sham
procedures, and drug interventions.
If conservative management does not give sufficient
symptom relief, the standard surgical option is
transurethral resection of the prostate. This involves
endoscopic removal of the inner (paraurethral) zones
of the enlarged prostate using a diathermy loop.
Although highly effective (average improvement in
score at 16 months is 10 to 18 points from baseline) in
relieving both symptoms and urodynamic obstruction,
this surgical procedure requires an anaesthetic and a
stay in hospital and carries a 5% risk of severe
haemorrhage.2 3 19 Because of this, newer procedures
using alternative energy sources (such as ultrasound,
laser, or microwave) have been developed. Some do
not require a general anaesthetic and can be carried out
in an outpatient setting with fewer adverse effects.
However, uncertainty remains about their long term
clinical and cost effectiveness.
Current standard
Transurethral resection of the prostate has been the
standard method of surgical management of clinical
BPH for 50 years. In recent times the procedure
accounted for more than 90% of prostatectomies for
BPH, although now the proportion is only 60-80%
because of new minimally invasive procedures.20
Improvements in endoscope design, diathermy units,
and bladder irrigation have reduced operating time
and risk of major morbidity.20 In respect of symptoms
associated with BPH, transurethral resection of the
prostate provides a consistent, long lasting, high level
of improvement in quality of life and peak urine flow
rate.2 19
New technology
Newer surgicaloptions forBPHcanbebroadlydivided
into “minimally invasive” and “tissue ablative” treat-
ments. Minimally invasive surgical treatments do not
remove tissue but cause in situ coagulative necrosis
through low energy heating devices (40-80°C).
These include: transurethral microwave therapy,
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Fig 2 Cumulative incidence of acute urinary retention and
invasive therapy for BPH. Adapted from McConnell et al
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radiofrequency transurethral needle ablation, and
transurethral or interstitial laser coagulation. Such
treatments can be carried out in an ambulatory care
environment under simple analgesia or sedation with
minimal anaesthesia, but they generally require a
prolonged period of bladder catheterisation. Most of
these treatments are used in men with smaller prostate
volumes (between 30 ml and 100 ml, and levels of
prostatic specific antigen<4.0 ng/ml) and no history of
urinary retention or previous prostate surgery.
Improvement in symptoms and urinary flow rate is
slightly poorer with minimally invasive treatments
than with transurethral resection of the prostate but
better than with α blocker therapy.16-18 Adverse effects
are less common than with transurethral resection of
the prostate, but repeat treatment or more invasive
treatment is needed for about 30% of men.23 19-23
Tissue ablative procedures use similar transurethral
instrumentation as transurethral resection of the
prostate but differing energy sources that can remove
tissue efficiently by vaporisation or resection but cause
less bleeding. They include laser resection or vaporisa-
tion, monopolar diathermy vaporisation, and bipolar
diathermy vaporisation/resection. Procedures such as
monopolar diathermy vaporisation and holmium laser
enucleationof theprostategive similar improvement in
symptoms and quality of life as transurethral resection
of the prostate, with less risk of major blood loss. The
improved haemostatic properties of these procedures
also allow earlier discharge fromhospital, saving about
one bed-day compared with transurethral resection of
the prostate. These procedures may offer particular
advantages for men taking anticoagulants and those
with cardiac or renal disease as the requirement for
irrigation of the bladder during and after surgery is
much reduced and haemoglobin concentrations are
maintained.
Adverse effects of surgery
Sexual side effects, particularly loss of ejaculation and
erectile dysfunction, are of concern to men having
prostate surgery. The risk of retrograde ejaculation is
significantly lower for minimally invasive procedures.
For ablative procedures, the risk is similar to transur-
ethral resection of the prostate.16-18 Reassuringly, the
occurrence of ejaculatory dysfunction does not seem to
lower quality of life much after prostate surgery. Rates
of erectiledysfunctionare similar across all procedures,
although lack of baseline data and spontaneous
development of erectile dysfunction in this older age
group are likely sources of bias.2 3 19 21-23
Incontinence is similar across all interventions with
the exception of transurethral needle ablation of the
prostate and laser coagulation (where reported rates
were lower), although comparative analysis is ham-
pered by variability in definition. The other most
pertinent long termadverse effect is the need for further
treatment owing to stricture formation, urinary reten-
tion, or disease relapse. Unfortunately, long term
follow-up data from randomised controlled trials are
not available. The best estimates concern transurethral
resection of the prostate, for which long term observa-
tional studies suggest a 1% annual risk of requiring
further treatment. Shorter term studies suggest further
treatment is more frequently required when minimally
invasive options such as transurethral microwave
thermotherapy are used, which probably reflects the
smaller amountof tissuedestroyedby theseprocedures.
Transurethral resection of the prostate remains
widely used throughout the world. In communities
with ageing populations and access to newer technol-
ogies the lower riskofbleedingduring laser resectionor
vaporisation techniquesmay be advantageous formen
with extensive comorbidity or long term anti-
coagulation. For most healthcare providers, however,
the benefits of widespread introduction of new
technologies are insufficient to justify the start-up and
consumable costs currently associated with these
procedures. For the UK NHS minimally invasive
options such as transurethral microwave thermother-
apy are not approved for use, and the availability of
newermethodsof ablation suchas laser vaporisationor
holmium laser enucleation of the prostate currently
depends on local enthusiasm and investment.
DATA SOURCES
We searched Medline and the Cochrane Library up to
November 2007 for randomised trials, systematic
reviews, evidence reports, and recent evidence based
guidelines from the American Urological Association,
European Urological Association, and the National
Institute for Health and Clinical Excellence.
ONGOING RESEARCH
 Discover and test new drugs to prevent or reduce benign prostatic hyperplasia
 Determine whether phytotherapies including saw palmetto and Pygeum africanum used
alone or in combination improve urinary symptoms and/or prevent progression
 Determine whether antimuscarinics plus α blockers are safe and more effective for men
with urinary symptoms than monotherapy alone
 Determine whether medical treatments (5α-reductase inhibitors) can reduce incidence
and mortality of prostate cancer
 Determine whether drugs typically used to treat erectile dysfunction are also effective for
treatment of urinary symptoms
 Determine factors limiting use and outcomes of minimally invasive surgery
ADDITIONAL EDUCATIONAL RESOURCES
 PatientPlus (www.patient.co.uk/showdoc/40002437/)—Comprehensive, free, up to
date health information as provided by general practitioners to patients during
consultations
 Foundation for Informed Medical Decision Making (www.fimdm.org)—Provides
information to help patients make sound decisions affecting their health and wellbeing
 Health Dialog (www.healthdialog.com)—Provides care management and analytical
services
 Cochrane Library (www.cochrane.org)—Publishes systematic reviews of the effects of
healthcare interventions
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When is referral to a urologist indicated?
The vast majority of men can receive appropriate
treatment by their primary care provider. In our earlier
article we said that referral to a urologist may be
indicated on the basis of patient preference or for
further assessment of men presenting with atypical
lower urinary tract signs or symptoms including new
onset urinary incontinence, haematuria, dysuria,
recurrent urinary tract infections, urinary obstruction,
or raised levels of prostate specific antigen.1 Referral
for potential surgical or minimally invasive inter-
ventions is appropriate for men with moderate to
severe bothersome symptoms who might prefer
surgery to medical treatment or for those in whom
medical treatment has not provided adequate symp-
tom improvement or is not well tolerated.
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SUMMARY POINTS
Treatment should improve patients’ symptoms and reduce progression and need for surgery
while minimising harms and costs
Management includes observation, lifestyle modification, drug treatment, minimally invasive
surgery, and surgical removal of prostate tissue
α blockers are the most effective drug for improving lower urinary tract symptoms and short
term quality of life
Combination treatment (α blockers and 5α-reductase inhibitors) reduces progression of
benignprostatic hyperplasia and need for surgery if the symptomsaremoderate or severe and
the prostate glands large, if taken for more than a year; adverse events increase
5α-reductase inhibitors may reduce risk of prostate cancer but may increase the risk of high
grade disease
Transurethral resection of the prostate results in the greatest improvement in symptoms and
flow rate, but adverse effects include the risk of surgery
Minimally invasive surgery can provide benefits comparable to transurethral resection of the
prostate, with fewer serious adverse effects. Short term repeat intervention and urinary
retention rates are higher than with transurethral resection of the prostate. Long term effect is
unclear
Health promotion: From clinic to classroom
Shewas a youngprimary school teacherwhohad attended
clinic with a history suggesting that her diet needed
attention. To alleviate her symptoms, she was advised to
increase her fruit and water intake throughout the day.
However, she felt that this was incompatible with her
lifestyle, citing the classroom as being a difficult place to
regularly snack on fruit or indeed drink water.
A letter was duly sent to the headmaster to obtain
permission for thepatient to eat her “five a day”portionsof
fruit during class time, and this was permitted. Some
months later, we heard that her symptoms had substan-
tially improved. Intriguingly, we were also told that the
children in her classroom, who had watched her eat,
pickedup thehabit of eating fruit ona regularbasis andhad
adopted it as part of their diet.
This shows the power of the classroom in promoting
health, particularly in following the philosophy of “preven-
tion is better than cure.”We should all strive to promote
health inourworkplaces,andperhapsthereisnobetterplace
tostartthanwithhospitalcanteensandourowneatinghabits.
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